SELECT-2:司美替尼联合多西他赛二线治疗晚期或转移性非小细胞肺癌的II期双盲随机安慰剂对照研究
SELECT-2研究将一线治疗后进展的晚期或转移性NSCLC患者按2:2:1随机分配至司美替尼75mg bid联合多西他赛60或75mg/m2,或安慰剂联合多西他赛75mg/m2,主要终点为PFS。结果显示两个司美替尼组对比安慰剂组在总体及KRAS野生型人群中均无PFS或OS的统计学显著改善,SEL+DOC 75组ORR较高但未转化为PFS延长。
要点
- 总体人群中位PFS:SEL+DOC 60组3.0个月、SEL+DOC 75组4.2个月 vs PBO+DOC 75组4.3个月。
- 总体人群中研究者评估ORR:SEL+DOC 75组33% vs PBO+DOC 75组14%,OR 3.26(90%CI 1.47, 7.95)。
- KRAS野生型患者中司美替尼联合多西他赛对比多西他赛单药未观察到临床获益。
核心结论
- 主要终点PFS未达到,SEL+DOC 75组较高的ORR未转化为总体或KRAS野生型人群的PFS延长。
- KRAS野生型患者中司美替尼联合多西他赛对比多西他赛单药未观察到临床获益,未报告新的或非预期安全性问题。
研究设计与样本
- II期双盲随机安慰剂对照研究,患者按2:2:1随机分配至SEL+DOC 60、SEL+DOC 75或PBO+DOC 75。
- 共212例患者随机,69%为KRAS野生型;初始入组不依赖KRAS状态,后修订方案仅纳入中心确认的KRAS野生型NSCLC。
- 司美替尼剂量为75mg bid,多西他赛剂量为60或75mg/m2;主要终点为PFS(RECIST 1.1)。
主要发现
- 总体人群中位PFS:SEL+DOC 60组3.0个月、SEL+DOC 75组4.2个月 vs PBO+DOC 75组4.3个月,HR分别为1.12(90%CI 0.8, 1.61)和0.92(90%CI 0.65, 1.31)。
- 总体人群中研究者评估ORR:SEL+DOC 75组33% vs PBO+DOC 75组14%,OR 3.26(90%CI 1.47, 7.95)。
- 总体及KRAS野生型人群中,两个司美替尼组对比PBO+DOC 75组均无PFS或OS的统计学显著改善。
关键数值与推荐
- 总体人群中位PFS:SEL+DOC 60组3.0个月、SEL+DOC 75组4.2个月 vs PBO+DOC 75组4.3个月。
- 总体人群中研究者评估ORR:SEL+DOC 75组33% vs PBO+DOC 75组14%,OR 3.26(90%CI 1.47, 7.95)。
- 总体人群中位PFS的HR:SEL+DOC 60组1.12(90%CI 0.8, 1.61),SEL+DOC 75组0.92(90%CI 0.65, 1.31)。
临床怎么用
- 对于一线治疗后进展的晚期或转移性NSCLC,司美替尼联合多西他赛未显示PFS或OS获益,不支持在KRAS野生型患者中使用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. PATIENTS AND METHODS: Patients who had disease progression after first-line anti-cancer therapy were randomized (2 : 2 : 1) to selumetinib 75 mg b.i.d. plus docetaxel 60 or 75 mg/m2 (SEL + DOC 60; SEL + DOC 75), or placebo plus docetaxel 75 mg/m2 (PBO + DOC 75). Patients were initially enrolled independently of KRAS mutation status, but the protocol was amended to include only patients with centrally confirmed KRAS wild-type NSCLC. Primary end point was progression-free survival (PFS; RECIST 1.1); statistical analyses compared each selumetinib group with PBO + DOC 75 for KRAS wild-type and overall (KRAS mutant or wild-type) populations. RESULTS: A total of 212 patients were randomized; 69% were KRAS wild-type. There were no statistically significant improvements in PFS or overall survival for overall or KRAS wild-type populations in either selumetinib group compared with PBO + DOC 75. Overall population median PFS for SEL + DOC 60, SEL + DOC 75 compared with PBO + DOC 75 was 3.0, 4.2, and 4.3 months, HRs: 1.12 (90% CI: 0.8, 1.61) and 0.92 (90% CI: 0.65, 1.31), respectively. In the overall population, a higher objective response rate (ORR; investigator assessed) was observed for SEL + DOC 75 (33%) compared with PBO + DOC 75 (14%); odds ratio: 3.26 (90% CI: 1.47, 7.95). Overall the tolerability profile of SEL + DOC was consistent with historical data, without new or unexpected safety concerns identified. CONCLUSION: The primary end point (PFS) was not met. The higher ORR with SEL + DOC 75 did not translate into prolonged PFS for the overall or KRAS wild-type patient populations. No clinical benefit was observed with SEL + DOC in KRAS wild-type patients compared with docetaxel alone. No unexpected safety concerns were reported. TRIAL IDENTIFIER: Clinicaltrials.gov NCT01750281.
引用
- Soria JC, Fülöp A, Maciel C, et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2017. PMID: 29045535. doi:10.1093/annonc/mdx628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。